-
Mashup Score: 0
PURPOSE: Cancer trial participants do not reflect the racial and ethnic diversity in the population of people with cancer in the United States. As a result of multiple system-, patient-, and provider-level factors, including implicit bias, cancer clinical trials are not consistently offered to all potentially eligible patients. MATERIALS AND METHODS: ASCO and ACCC evaluated the utility (pre- and…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Is Mitochondrial Metabolism a New Predictive Biomarker for Antiprogrammed Cell Death Protein-1 Immunotherapy? - 1 year(s) ago
This article addresses the importance of mitochondrial metabolism in response to antiprogrammed cell death protein-1 antibodies. In this commentary, we have outlined how this concept can answer the…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP Commentary: Despite some remarkable results, a minority of pts benefit from anti–PD-1 #immunotherapy. Recent studies show the importance of mitochondrial biology in #ICI; can mitochondrial metabolism be used as a novel predictive biomarker? 👉 https://t.co/jPMlmuCSy3
-
-
Mashup Score: 0
Recent data support incorporation of immune checkpoint inhibitors into the treatment armamentarium for esophageal, gastroesophageal junction, and gastric (esophagogastric) cancer. This practical review focuses on clinical trials that influenced US Food and Drug Administration approvals and treatment guidelines in esophagogastric cancer, including the impact of location, stage, histology, human…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP @DrDanielKing clinical review the use of #immunotherapy #immuneCheckpointInhibitors for the treatment of gastric and esophageal/GEJ cancer based on histology, CPS and HER2 status. ➡️ https://t.co/pyfUUMpFHB #esocsm #immunoonc https://t.co/aQU3pcrcGM
-
-
Mashup Score: 1
Direct release of oncology test results to patient portals calls for new communication skills training.
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP Editorial: Direct release of oncology test results to patient portals after the #21stCenturyCuresAct calls for new communication skills training for oncologists. ➡️ https://t.co/I6F6R8l30y @Jessica_Hahne https://t.co/sNKImkZ0ky
-
-
Mashup Score: 1Care Fragmentation, Faulty Communication, and Documentation Lapses Derail a Treatment Plan - 1 year(s) ago
This is the second Cancer Morbidity, Mortality, and Improvement Rounds, a series of articles intended to explore the unique safety risks experienced by oncology patients through the lens of quality improvement, systems and human factors engineering, and cognitive psychology. This case describes the care of a patient who was diagnosed with locally advanced lung cancer during the COVID-19 pandemic;…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP Cancer Morbidity, Mortality, & Improvement Rounds: This case illustrates the importance of multiD care, discusses factors that led to communication gaps, & examines how we should assign accountability across dispersed health care systems. ➡️ https://t.co/8LlRVQzAsk https://t.co/n4hFLss7yu
-
-
Mashup Score: 3Cannabis Use in Patients With Cancer: A Clinical Review - 2 year(s) ago
Cannabis use and interest continues to increase among patients with cancer and caregivers. High-quality research remains scant in many areas, causing hesitancy or discomfort among most clinical providers. Although we have limitations on hard outcomes, we can provide some guidance and more proactively engage in conversations with patients and family about cannabis. Several studies support the…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What’s 🔥 this week in #JCOOP? #Cannabis use and interest continues to ⬆️ in patients w/ #cancer & caregivers. The formulations, pharmacokinetics, indications, evidence basis, & cancer-specific concerns of #MedicalCannabis are reviewed here. 👉 https://t.co/L7wBJ1c2Jp https://t.co/NAV0vtKAIa
-
-
Mashup Score: 12022_09 JCO OP Reader Study - 2 year(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP wants to hear from you. Take our reader survey today! ✏️ https://t.co/3hk6JduJ1J
-
-
Mashup Score: 0Risk Stratification for Patients With Cancer and Febrile Neutropenia: Art or Science? - 2 year(s) ago
The advent of multidrug chemotherapy regimens in the latter half of the 20th century has substantially improved survival for patients with a wide range of hematologic and solid tumor malignancies. These survival gains come with a host of treatment-related toxicities, and febrile neutropenia is among the most feared complications of cytotoxic chemotherapy. The risk of serious complications among…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP Commentary: "Risk Stratification for Patients With Cancer & #FebrileNeutropenia: Art or Science?" How then can we move forward to improve safe, effective, and efficient care for patients w chemotherapy-related febrile neutropenia? 👉 https://t.co/qhbOyvrTyj
-
-
Mashup Score: 0
The Enhancing Oncology Model is planned to begin July of 2023. While the deadline to apply has passed, oncology practices still have much to consider when deciding whether to sign a participation a…
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#JCOOP @ASCO Editorial: The #EnhancingOncologyModel #EOM is planned to begin July 2023 📅. While the deadline to apply has passed, oncology practices still have much to consider when deciding whether to sign✍️ a participation agreement. https://t.co/5QDJEkgbke https://t.co/xCGKbcXALT
-
-
Mashup Score: 0Challenges of Reaching Patients With Cancer on Social Media: Lessons From the Failed #CancerRealTalk Experience - 2 year(s) ago
Oncologists play a key role in dispelling misinformation on social media; see these lessons learned.
Source: JCO Oncology PracticeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
What’s 🔥 this Week #JCOOP? “ ... many online sources, social media in particular, are often not vetted by physicians or other health care professionals and have a high risk of containing misinformation.” Read the full article here 👉 https://t.co/ukZbyNg7kF #OncTwitter https://t.co/yWus5xLipl
-
Results in #JCOOP from @ASCO & @ACCCBuz Just ASK™ Implicit Bias Training pilot showed an increase in knowledge of the key concepts of #implicitbias, and of strategies to address implicit bias & diversity concerns in cancer #clinicaltrials. https://t.co/d2BxN0V6A8 #healthequity